Document:

Exhibit

Exhibit 10.6
Execution Version

CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY [*****] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

AMENDMENT NO. 4 TO SERVICING AGREEMENT

THIS AMENDMENT NO. 4 TO SERVICING AGREEMENT (this “Amendment”) is made as of June 29, 2018 by and between GreenSky, LLC, a Georgia limited liability company (“Servicer”), and Fifth Third Bank, an Ohio-chartered, FDIC-insured bank (“Lender”).  Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Servicing Agreement (as defined herein).
WITNESSETH:
WHEREAS, Lender and Servicer have previously entered into that certain Servicing Agreement dated as of August 25, 2016, as amended (the “Servicing Agreement”); 
WHEREAS, concurrent with the execution hereof, Lender, Servicer and [*****] have entered into that certain Purchase and Sale Agreement (the “Purchase and Sale Agreement”), dated as of the date hereof, pursuant to which Lender is acquiring a group of loans having an aggregate principal amount as specified therein (collectively, the “June 2018 Acquired Loans”), and pursuant to which Lender and Servicer have agreed to treat the loans comprising the June 2018 Acquired Loans as if such loans were originally originated under the Loan Origination Agreement and serviced at all times under the Servicing Agreement, except as set forth therein and as otherwise set forth in this Amendment; and
WHEREAS, in connection with the Purchase and Sale Agreement, Lender and Service desire to modify certain terms of the Servicing Agreement as set forth herein;
NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Lender and Servicer hereby agree as follows:
1.    The Servicing Agreement is hereby amended as follows:
a.    The following is hereby inserted in Section 1.01 of the Servicing Agreement, in alphabetical order:

““June 2018 Acquired Loans” shall mean the “Loans” as defined in that certain Purchase and Sale Agreement between Lender, Servicer and [*****] dated as of June 29, 2018, which were acquired by Lender pursuant thereto.”

b.    The following is hereby inserted in Section 1.01 of the Servicing Agreement, in alphabetical order:

““Charged-Off June 2018 Acquired Loans” shall mean the 2018 Acquired Loans that were identified to Lender as a “Charged-Off Loan” in Appendix B to that certain Purchase and Sale Agreement between Lender, Servicer and [*****] dated as of June 29, 2018.”

1

CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY [*****] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

c.    Section 3.01(b) of the Servicing Agreement is hereby amended by deleting Section 3.01(b)(vi) and substituting the following in lieu thereof:

“(vi)     [*****].”

d.    Section 3.01 of the Servicing Agreement is hereby amended by adding the following as a new Section 3.01(f) immediately after Section 3.01(e):

“(f)    [*****].”

e.    The first sentence of Section 3.01(d) of the Servicing Agreement is hereby deleted in its entirety and the following is substituted in lieu thereof:

“[*****].”

c.    Section 3.01(d)(iv) of the Servicing Agreement is hereby amended by deleting the definition of “[*****]” therein and substituting the following in lieu thereof:

“[*****].”

d.    Section 3.02 of the Servicing Agreement is hereby amended by adding the following to the end of the definition of “[*****]” therein (immediately prior to the definition of “[*****]”):

“[*****].”

2.    Except as expressly amended hereby, the Servicing Agreement shall remain in full force and effect.
3.    This Amendment may be executed and delivered by Lender and Servicer in facsimile or PDF format and in any number of separate counterparts, all of which, when delivered, shall together constitute one and the same document.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

SERVICER:

GREENSKY, LLC

By:     /s/ Robert Partlow            
Name:    Robert Partlow
Title:    Chief Financial Officer

    

LENDER:

FIFTH THIRD BANK

By:     /s/ Ben Hoffman            
Name:    Ben Hoffman
Title:    Senior Vice President

By:     /s/ Richard Stein            
Name:    Richard Stein
Title:    Executive Vice President

2Exhibit 10.2

 

AGREEMENT

 

This
Agreement (“Agreement”) is made by and between MYnd Analytics, Inc. (hereinafter “MYnd” or “Company”)
and George C. Carpenter, IV (hereinafter “Employee”) dated as of May 25, 2018.

 

Between
March 1, 2015 and July 31, 2015, the Employee agreed to defer his salary in the amount of $9,250.00 per month for a total of $101,500.00.
The Employee hereby agrees to receive 11,205 shares of common restricted stock under the Company’s Amended and Restated
2012 Omnibus Incentive Compensation Plan (the “2012 Plan”
); which is granted and vest immediately upon the date of this Agreement to reduce the amount owe by the Company by $25,437.50
(25% of the outstanding amount). The outstanding amount as of the date of this Agreement of deferred salary is $76,062.50.

 

The
Parties hereby agree that this Agreement resolves any outstanding defer salary or wages, as to the 25% listed above only, that
the Employee might be owed by the Company under California Labor Code, including Section 200 et seq., relating to salary, commission,
compensation, benefits and other matters.

 

Agreed
and Accepted:

 

	Employee

                            

        By:/s/
        George C. Carpenter, IV

        George
        C. Carpenter, IV
	MYnd
                           Analytics, Inc.

                            

                           By:/s/
                           Don D’Ambrosio

        Don
        D’Ambrosio, CFORESTATED

LICENSE
AGREEMENT

 

This
agreement (“Agreement”) is entered into as of July 1, 2017, (the “Effective Date”) by and between TearLab
Corporation, a Delaware corporation having an address at 9980 Huennekens St., Suite 100, San Diego, CA 92121 (“LICENSEE”)
and The Regents of the University of California, a California public corporation having its statewide administrative offices at
1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an
address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive,
La Jolla, California 92093-0910 (“UCSD”).

 

BACKGROUND

 

Whereas,
the invention disclosed in UCSD Disclosure Docket No. SD2002-180 and titled “Volume Independent Tear Film Osmometer”
(“Invention”), was made in the course of research at UCSD by Dr. Benjamin Sullivan (hereinafter, the “Inventor”)
and is covered by Patent Rights as defined below.

 

Whereas,
LICENSEE has previously entered into an exclusive license agreement for the commercial development of Invention (UCSD License
Agreement #2003-03-0433 effective March 12, 2003), including Amendment #1 (dated June 9, 2003), Amendment #2 (dated September
5, 2005), Amendment #3 (dated July 7, 2006), Amendment #4 (dated October 9, 2006) and Amendment #5 (dated July 9, 2007) (collectively
the “Existing License”).

 

Whereas,
LICENSEE has successfully brought products encompassing the Invention to the commercial market, has satisfied all developmental
milestones contained in the Existing License as of the Effective Date and is in good standing with regard to the Existing License.

 

Whereas,
LICENSEE is presently developing the TearLab DiscoveryTM System, (“Discovery”), as a new Licensed Product
under this Agreement, as described in LICENSEE’S March 2, 2018 United States Securities and Exchange Commission, Form 10-K
filing. Discovery, if approved for commercial sale, will create new market opportunities for Invention and supporting that development
is in the public interest.

 

Whereas,
to facilitate LICENSEE’S future business activities and UNIVERSITY’S stewardship of the Invention and Patent Rights,
it is the mutual desire of the parties to enter this new Agreement and concurrently terminate the Existing License.

 

Whereas,
as of the Effective Date, this Agreement shall govern the relationship between LICENSEE and UNIVERSITY with regard to the Invention
and Patent Rights. For clarity, any obligations due to UNIVERSITY by LICENSEE as of the Effective Date under the Existing License
shall remain in effect, in accordance with Paragraph 7.3 of the Existing License, “Survival on Termination”. Likewise,
any ongoing matters regarding Patent Rights subject to the Existing License shall transfer under this Agreement as of the Effective
Date.

 

    	-1-

    	 

    

 

The
parties agree as follows:

 

ARTICLE
1. DEFINITIONS

 

The
terms, as defined herein, have the same meanings in both their singular and plural forms.

 

1.1
“Affiliate” means any corporation, firm, limited liability company, partnership or other entity that directly or indirectly
Controls or is Controlled by or is under common control with LICENSEE. “Control” means (i) having the actual, present
capacity to elect a majority of the directors of such entity; (ii) having the power to direct at least forty percent (40%) of
the voting rights entitled to elect directors; or (iii) in any country where the local law will not permit foreign equity participation
of a majority, ownership or control, directly or indirectly, of the maximum percentage of such outstanding stock or voting rights
permitted by local law.

 

1.2
“Commercial Sales” means, with respect to Discovery, the first sale in an arms-length transaction to a Third-Party
by LICENSEE, its Affiliates or a Sublicensee.

 

1.3
“Field” means all uses of Patent Rights.

 

1.4
“Fundamental Transaction means the LICENSEE engaging in one or more transactions with another party that results in that
party acquiring more than 50% of the LICENSEES outstanding shares of common stock.

 

1.5
“Licensed Product” means any service, composition or product which is composed of or incorporates the Invention, or
that is claimed in Patent Rights, or the manufacture, use, sale, offer for sale, or importation of which would constitute, but
for the license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe or contributory infringement,
of any pending or issued claim within the Patent Rights.

 

1.6
“Net Sales” means the total of the gross invoice prices of Licensed Products sold or leased by LICENSEE, Sublicensee,
Affiliate, or any combination thereof, less the sum of the following actual and customary deductions where applicable and separately
listed: cash, trade, or quantity discounts or rebates (as allowed under applicable law); sales tax, use tax, tariff, import/export
duties or other excise taxes imposed on particular sales (except for value-added and income taxes imposed on the sales of Licensed
Product in foreign countries); transportation charges; or credits to customers because of rejections or returns. For purposes
of calculating Net Sales, transfers to a Sublicensee or an Affiliate of Licensed Product under this Agreement for (a) end use
(but not resale) by the Sublicensee or Affiliate shall be treated as sales by LICENSEE at list price of LICENSEE, or (b) resale
by a Sublicensee or an Affiliate shall be treated as sales at the list price of the Sublicensee or Affiliate.

 

1.7
“Patent Costs” means all out-of-pocket expenses for the preparation, filing, prosecution, and maintenance of all United
States and foreign patents included in Patent Rights. Patent Costs include out-of-pocket expenses for patentability opinions,
inventorship determination, preparation and prosecution of patent application, re-examination, re-issue, interference, post-grant
review and other administrative proceedings in patent offices, and opposition activities, and the like, related to patents or
applications in Patent Rights.

 

1.8
“Patent Rights” means UNIVERSITY’s rights in the claims of any of the following: the U.S. patents and patent
applications listed in Exhibit A; and continuing applications thereof including divisions, substitutions, and continuations-in-part
(but only to the extent the claims thereof are entirely supported in the specification and entitled to the priority date of the
parent application); any patents issuing on said applications including reissues, reexaminations and extensions; and any corresponding
foreign applications or patents.

 

    	-2-

    	 

    

 

1.9
“Sublicense” means an agreement into which LICENSEE enters with a third party that is not an Affiliate for the purpose
of (a) granting certain rights; (b) granting an option to certain rights; or (c) forbearing the exercise of any rights, granted
to LICENSEE under this Agreement. “Sublicensee” means a third party with whom LICENSEE enters into a Sublicense.

 

1.10
“Term” means the period of time beginning on the Effective Date and ending on the expiration date of the longest-lived
Patent Rights.

 

1.11
“Territory” means worldwide, to the extent Patent Rights exist.

 

ARTICLE
2. GRANTS

 

2.1
License. Subject to the limitations set forth in this Agreement, UNIVERSITY hereby grants to LICENSEE an exclusive license
under Patent Rights to make, use, sell, offer for sale, and import Licensed Products in the Field within the Territory and during
the Term. LICENSEE may extend such license to its AFFILIATES, provided that LICENSEE will be responsible for such AFFILIATES compliance
under this Agreement.

 

2.2
Sublicense. 

 

	 	(a)
    	The
    license granted in Paragraph 2.1 includes the right of LICENSEE to grant Sublicenses to third parties during the Term but
    only for as long as the license to Patent Rights is exclusive.
	 	 	 
	 	(b)
    	With
    respect to Sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall:
	 	 	 
	 	 	(i)
    not receive, or agree to receive, anything of value in lieu of cash as consideration from a third party under Sublicense without
    the express written consent of UNIVERSITY; 
	 	 	 
	 	 	(ii)
    to the extent applicable, include all of the rights of and obligations due to UNIVERSITY and contained in this Agreement;
	 	 	 
	 		(iii)promptly
    provide UNIVERSITY with a copy of each Sublicense issued; and
	 	 	 
	 	 	(iv)
    collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees and summarize and
    deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees.

 

(c)
Upon termination of this Agreement for any reason, UNIVERSITY shall agree to assume all Sublicensees as direct licensees under
Patent Rights subject to: (i) UNIVERSITY will not incur any additional obligations not already present in this Agreement; (ii)
each assumed Sublicensee will be in good-standing under the terms of their Sublicense at time of assumption by UNIVERSITY; and
(3) each assumed Sublicensee shall, within thirty (30) days, confirm in writing their consent to become a direct licensee of UNIVERSITY.
For the avoidance of doubt, AFFILIATES’ rights extended by LICENSEE also terminate upon termination of this Agreement.

 

    	-3-

    	 

    

 

2.3
Reservation of Rights. UNIVERSITY reserves the right to:

 

(a)
use the Invention and Patent Rights for educational and research purposes;

 

(b)
publish or otherwise disseminate any information about the Invention and Patent Rights at any time; and

 

(c)
allow other nonprofit institutions to use, publish, or otherwise disseminate any information about Invention and Patent Rights
for educational and research purposes.

 

ARTICLE
3. CONSIDERATION

 

3.1
Fees and Royalties. The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this
Agreement are partial consideration for the license granted herein to LICENSEE under Patent Rights. LICENSEE shall pay UNIVERSITY:

 

(a)
an earned royalty on Net Sales of Licensed Products by LICENSEE, Sublicensees, and/or Affiliates in accordance with the below
Royalty Rate Table On Effective Date, provided, however, that in the event LICENSEE is required to pay royalties to one or more
third parties for patent rights necessary to make, use or sell Licensed Products, LICENSEE may deduct $0.50 from the earned royalties
payable to UNIVERSITY for every $1.00 LICENSEE actually pays to said third parties; provided, however, in no event shall the amount
payable to UNIVERSITY be less than fifty percent (50%) of the amount otherwise due;

 

Royalty
Rate Table On Effective Date

 

	Quarterly
    Net Sales beginning with Effective Date	 	Royalty
    Rate
	Sales
    up to US$10,000,000.00	 	3.0%

        

	Sales
    up to US$20,000,000.00	 	3.5%
	Sales
    above US$20,000,000.00	 	4.25%

 

For
clarity, for any given calendar year quarter, only one royalty rate will apply to the total Net Sales for that quarter, i.e. Net
Sales will not be apportioned between different royalty rates within any given calendar year quarter. By way of example, if Net
Sales for a given calendar year quarter equal $18,000,000.00, the entire sum will be assessed at the 3.5% royalty rate.

 

Should
LICENSEE enter into a Fundamental Transaction during the term of this agreement, LICENSEE shall pay UNIVERSITY an earned royalty
on Net Sales of Licensed Products by LICENSEE, Sublicensees, and/or Affiliates in accordance with the below Royalty Rate Table
After Fundamental Transaction, provided, however, that in the event LICENSEE is required to pay royalties to one or more third
parties for patent rights necessary to make, use or sell Licensed Products, LICENSEE may deduct $0.50 from the earned royalties
payable to UNIVERSITY for every $1.00 LICENSEE actually pays to said third parties; provided, however, in no event shall the amount
payable to UNIVERSITY be less than fifty percent (50%) of the amount otherwise due;

 

Royalty
Rate Table After Fundamental Transaction

 

	Quarterly
    Net Sales beginning with Effective Date	 	Royalty
    Rate
	Sales
    up to US$10,000,000.00	 	3.5%

        

	Sales
    up to US$20,000,000.00	 	4.0%
	Sales
    above US$20,000,000.00	 	4.75%

 

    	-4-

    	 

    

 

(b)
twenty percent (20%) of all Sublicense fees received by LICENSEE from its Sublicensees that are not earned royalties. Such Sublicense
Fees will exclude reimbursement of expenses, Licensed Product development costs or other pass through costs borne by the Sublicensee.

 

(c)
should LICENSEE enter into a Fundamental Transaction, LICENSEE shall pay to UNIVERSITY a milestone payment equal to five-hundred
thousand dollars (US$500,000.00). This provision shall survive termination or expiration of this Agreement.

 

(d)
a milestone payment equal to one and one-quarter percent (1.25%) of the cumulative Net Sales of Licensed Products by LICENSEE,
Sublicensees, and/or Affiliates, for the period beginning on the Effective Date and ending two (2) years thereafter. This milestone
payment will not be due if LICENSEE has commenced commercial sales of Discovery on or before July 1, 2019. Otherwise, payment
will be due on August 1, 2019.

 

All
fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(d) above shall be paid by LICENSEE pursuant to Paragraph
4.3 and shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1.

 

3.2
Patent Costs. LICENSEE shall reimburse UNIVERSITY for all past Patent Costs (prior to the Effective Date and not otherwise
paid under the Existing Agreement). LICENSEE shall reimburse UNIVERSITY all future (on or after the Effective Date) Patent Costs
incurred during the Term and in the Territory within thirty (30) days following the date an itemized invoice is sent from UNIVERSITY
to LICENSEE.

 

3.3
Due Diligence.

 

	 	(a)
    	LICENSEE
    shall, either directly or through its Affiliate(s) or Sublicensee(s):
	 	 	 
	 	 	(i)
    continue to fill the market for Licensed Products for the remainder of the Term;
	 	 	 
	 	 	(ii)
    not abandon any existing regulatory approvals covering Licensed Products in the Territory; 
	 	 	 
	 	 	(iii)
    commence commercial sales of Discovery on or before July 1, 2019; and
	 	 	 
	 	 	(iv)
    secure all necessary governmental approvals for the continued and/or future sale of Licensed Products.

 

(b)
If LICENSEE fails to perform any of its obligations specified in Paragraphs 3.3(a)(i)-(iv), then UNIVERSITY shall have the right
and option to either terminate this Agreement or change LICENSEE’s exclusive license under Patent Rights to a nonexclusive
license. This right, if exercised by UNIVERSITY, supersedes the rights granted in Article 2.

 

    	-5-

    	 

    

 

ARTICLE
4. REPORTS, RECORDS AND PAYMENTS

 

4.1
Reports. 

 

	 	(a)
    	Royalty
    Reports. 
	 	 	 
	 	 	LICENSEE
    shall submit to UNIVERSITY quarterly royalty reports on or before each February 28, May 31, August 31 and November 30 of each
    year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently
    completed calendar quarter and shall show:
	 	 	 
	 	 	(i)
    the date of first commercial sale of a Licensed Product in each country;
	 	 	 
	 	 	(ii)
    the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar
    year and the royalties, in US dollars, payable with respect thereto;
	 	 	 
	 	 	(iii)
     the number of each type of Licensed Product sold;
	 	 	 
	 	 	(iv)
    Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect
    thereto;
	 	 	 
	 	 	(v)
    the method used to calculate the royalties; and
	 	 	 
	 	 	(vi)
    the exchange rates used.

 

If
no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period,
LICENSEE shall so report. The reports referred to in this Paragraph 4.1(a) should be marked with the following title and case
number: “License Agreement between UCSD and TearLab for case SD2002-180.” Reports shall be submitted as an attachment
to UCSD’s email address: oic-reports@ucsd.edu.

 

4.2
Records & Audits.

 

(a)
LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed Products
manufactured, used, sold, offered for sale, and imported and Sublicense fees received under this Agreement. Such records shall
be retained by LICENSEE for at least five (5) years following a given reporting period.

 

(b)
All records shall be available during normal business hours for inspection at the expense of UNIVERSITY by UNIVERSITY’s
Internal Audit Department or by a Certified Public Accountant selected by UNIVERSITY and in compliance with the other terms of
this Agreement for the sole purpose of verifying reports and payments or other compliance issues. Such inspector shall not disclose
to UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement
or other compliance issues. In the event that any such inspection shows an under reporting and underpayment in excess of five
percent (5%) for any twelve-month (12-month) period, then LICENSEE shall pay the cost of the audit as well as any additional sum
that would have been payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest charge at a rate of ten percent
(10%) per year. Such interest shall be calculated from the date the correct payment was due to UNIVERSITY up to the date when
such payment is actually made by LICENSEE. For underpayment not in excess of five percent (5%) for any twelve (12)-month period,
LICENSEE shall pay the difference within thirty (30) days without interest charge or inspection cost.

 

4.3
Payments.

 

(a)
All fees, reimbursements and royalties due UNIVERSITY shall be paid in United States dollars and all checks shall be made payable
to “The Regents of the University of California”, referencing “UCSD OIC”, and sent to UNIVERSITY according
to Paragraph 10.1 (Correspondence).

 

(b)
Royalty Payments.

 

    	-6-

    	 

    

 

(i)
Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

 

(ii)
LICENSEE shall pay earned royalties quarterly on or before February 28, May 31, August 31 and November 30 of each calendar year.
Each such payment shall be for earned royalties accrued within LICENSEE’s most recently completed calendar quarter.

 

(c)
Late Payments. In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall
pay to UNIVERSITY interest charges at a rate of ten percent (10%) per year. Such interest shall be calculated from the date payment
was due until actually received by UNIVERSITY.

 

(d)
Taxes. Taxes imposed by any governmental agency on any payments to be made to UNIVERSITY by LICENSEE hereunder shall be paid by
LICENSEE without deduction from any payment due to UNIVERSITY hereunder.

 

ARTICLE
5. PATENT MATTERS

 

5.1
Patent Prosecution and Maintenance.

 

(a)
Provided that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant to Paragraph 3.2, UNIVERSITY shall diligently prosecute
and maintain the United States and, if available, foreign patents, and applications in Patent Rights using counsel of its choice.
For purposes of clarity, if LICENSEE is not current in reimbursing UNIVERSITY for such Patent Costs, UNIVERSITY shall have no
obligation to incur any new Patent Costs under this Agreement or to further prosecute Patent Rights or file any new patent applications
under Patent Rights. UNIVERSITY shall provide LICENSEE with copies of all relevant documentation relating to such prosecution
and LICENSEE shall keep this documentation confidential. The counsel shall take instructions only from UNIVERSITY, and all patents
and patent applications in Patent Rights shall be assigned solely to UNIVERSITY. UNIVERSITY shall take into consideration any
actions recommended by LICENSEE to protect the Licensed Products contemplated to be sold by LICENSEE under this Agreement. UNIVERSITY
shall in any event control all patent filings and all patent prosecution decisions and related filings (e.g., responses to office
actions) shall be at UNIVERSITY’s final discretion (prosecution includes, but is not limited to, interferences, oppositions
and any other inter partes or ex parte matters originating in a patent office).

 

(b)
Should LICENSEE elect to terminate its reimbursement obligations with respect to any patent application or patent in Patent Rights,
LICENSEE shall have no further license with respect to such Patent Rights under this Agreement. Non-payment of any portion of
Patent Costs with respect to any application or patent may be deemed by UNIVERSITY as an election by LICENSEE to terminate its
reimbursement obligations with respect to such application or patent. UNIVERSITY is not obligated at any time to file, prosecute,
or maintain Patent Rights in a country, where, for that country’s patent application or patent LICENSEE is not paying Patent
Costs, or to file, prosecute, or maintain Patent Rights to which LICENSEE has terminated its license hereunder.

 

    	-7-

    	 

    

 

5.2
Patent Infringement.

 

(a)
If UCSD (based on actual knowledge of the licensing professional responsible for administering this Invention) or LICENSEE learns
of potential infringement of commercial significance of any patent licensed under this Agreement, the knowledgeable party promptly
will inform the other party of the infringement and provide evidence of infringement available to the knowledgeable party (“Infringement
Notice”). In a jurisdiction where LICENSEE has exclusive rights under this Agreement, neither UNIVERSITY nor LICENSEE will
notify a third party (including the infringer) of infringement or put such third party on notice of the existence of any Patent
Rights without first obtaining consent of the other. UNIVERSITY and LICENSEE agree to discuss and determine how best to proceed.
If LICENSEE notifies a third party of infringement or puts such third party on notice of the existence of any Patent Rights regarding
such infringement without first obtaining the written consent of UNIVERSITY and UNIVERSITY is sued for declaratory judgment (or
its equivalent), UNIVERSITY will have the right to terminate this Agreement immediately, notwithstanding Paragraph 7.1. UNIVERSITY
and LICENSEE will use diligent efforts to cooperate with each other to terminate such infringement without litigation. If such
infringement has not ended within ninety (90) days of the effective date of the Infringement Notice, then LICENSEE may initiate
suit; and, if such infringement has not ended within one hundred and twenty (120) days of the effective date of the Infringement
Notice, and LICENSEE has not initiated suit, then UNIVERSITY may initiate suit.

 

(b)
Notwithstanding the foregoing:

 

(i)
UNIVERSITY may not be joined in any suit without its prior written consent;

 

(ii)
LICENSEE may not admit liability or wrongdoing on behalf of UNIVERSITY without its prior written consent;

 

(iii)
Each party will cooperate with the other in litigation initiated under Paragraph 5.2, but at the expense of the party who initiated
the suit;

 

(iv)
If UNIVERSITY is joined in any suit under Paragraph 5.2, LICENSEE will pay all of UNIVERSITY’s costs;

 

(v)
If UNIVERSITY is a party to a suit under Paragraph 5.2, then the recovery to UNIVERSITY will be equal to fifteen percent (15%)
of net recoveries after reimbursement of LICENSEE’S and UNIVERSITY’S out of pocket costs related to the suit;

 

(vi)
Any agreement made by LICENSEE for purposes of settling litigation or other dispute regarding Patent Rights will comply with the
requirements of Paragraph 2.2 (Sublicense); and

 

(vii)
If LICENSEE or UCSD (but not both) sues a third party for infringement of Patent Rights, then the non-suing party may not thereafter
sue such infringer for the acts of infringement raised in the suit.

 

5.3
Patent Marking. LICENSEE shall mark all Licensed Products made, used, sold, offered for sale, or imported under the terms
of this Agreement, or their containers, in accordance with the applicable patent marking laws. LICENSEE shall be responsible for
all monetary and legal liabilities arising from or caused by (a) failure to abide by applicable patent marking laws and (b) any
type of incorrect or improper patent marking.

 

ARTICLE
6. EXPORT CONTROL AND REGISTRATION

 

6.1
Export Control. LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer of Licensed
Products, and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations
and the Export Administration Regulations.

 

    	-8-

    	 

    

 

6.2
Governmental Approval or Registration. If this Agreement or any associated transaction is required by the law of any nation
to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE
shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with
such reporting or approval process.

 

ARTICLE
7. TERMINATION OR EXPIRATION OF THE AGREEMENT

 

7.1
Termination by UNIVERSITY.

 

(a)
If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice of default (“Notice
of Default”) to LICENSEE. If LICENSEE fails to cure the default within sixty (60) days of the Notice of Default, UNIVERSITY
may terminate this Agreement and the license granted herein by a second written notice (“Notice of Termination”) to
LICENSEE. If a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of
that notice. Termination shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall
not impair any accrued right of UNIVERSITY. During the term of any such Notice of Default or period to cure, to the extent the
default at issue is a failure to pay past or ongoing patent costs as provided for under this Agreement, UNIVERSITY shall have
no obligation to incur any new patent costs under this Agreement and shall have no obligation to further prosecute Patent Rights
or file any new patents under Patent Rights.

 

(b)
This Agreement will terminate immediately, without the obligation to provide 60 days notice as set forth in Paragraph 7.1(a),
if LICENSEE files a claim that any portion of UNIVERSITY’s Patent Rights is invalid or unenforceable where the filing is
by the LICENSEE, a third party on behalf of the LICENSEE, or a third party at the written urging of the LICENSEE.

 

7.2
Termination by LICENSEE. 

 

(a)
LICENSEE shall have the right at any time and for any reason to terminate this Agreement upon a ninety (90)-day written notice
to UNIVERSITY. Said notice shall state LICENSEE’s reason for terminating this Agreement.

 

(b)
Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement
prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective.
Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination.

 

7.3
Survival on Termination or Expiration. The rights and obligations under Paragraphs and Articles 3.1(a) (license issue fee),
3.1(c), 4 (Reports, Records and Payments), 8 (Limited Warranty and Indemnification), 9 (Use of Names and Trademarks), 10.2 (Secrecy),
and 10.5 (Failure to Perform) shall survive the termination or expiration of this Agreement.

 

    	-9-

    	 

    

 

ARTICLE
8. LIMITED WARRANTY AND INDEMNIFICATION

 

8.1
No Warranty.

 

(a)
The license granted herein provided “AS IS” and without WARRANTY OF MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR
PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed Product or
the use of Patent Rights will not infringe any other patent or other proprietary rights.

 

UNIVERSITY
WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR
INTELLECTUAL PROPERTY INFRINGEMENT OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED
BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION
OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF UNIVERSITY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES. ALSO, UNIVERSITY WILL NOT BE LIABLE FOR ANY DIRECT DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES,
JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO PATENT RIGHTS TO THE EXTENT ASSIGNED, OR OTHERWISE LICENSED, BY UNIVERSITY’S
INVENTORS TO THIRD PARTIES.

 

(b)
Nothing in this Agreement shall be construed as:

 

(i)
a warranty or representation by UNIVERSITY as to the validity, enforceability, or scope of any Patent Rights;

 

(ii)
a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement
is or shall be free from infringement of patents of third parties;

 

(iii)
an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Paragraph
5.2 hereof;

 

(iv)
conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights,
or any technology, regardless of whether those patents are dominant or subordinate to Patent Rights;

 

(v)
an obligation to furnish any know-how not provided in Patent Rights.

 

8.2
Indemnification and Insurance.

 

(a)
LICENSEE will, and will require Sublicensees to, indemnify, hold harmless, and defend UNIVERSITY and its officers, employees,
and agents; the sponsors of the research that led to the Invention; and inventors of patents or patent applications under Patent
Rights, and their employers; against any and all claims, suits, losses, damages, costs, fees, and expenses resulting from, or
arising out of, the exercise of this license or any Sublicense. This indemnification will include, but will not be limited to,
any product liability.

 

    	-10-

    	 

    

 

(b)
LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain,
keep in force and maintain insurance as follows:

 

(i)
commercial general liability insurance (contractual liability included) with limits of at least:

 

(A)
each occurrence, one million dollars (US$1,000,000.00);

 

(B)
products/completed operations aggregate, five million dollars (US$5,000,000.00);

 

(C)
personal and advertising injury, one million dollars (US$1,000,000.00); and

 

(D)
general aggregate five million dollars (US$5,000,000.00). If the above insurance is written on a claims-made form, it shall
continue for three (3) years following termination or expiration of this Agreement. The insurance shall have a
retroactive date of placement prior to or coinciding with the Effective Date;

 

(ii)
Worker’s Compensation as legally required in the jurisdiction in which the LICENSEE is doing business; and

 

(iii)
the coverage and limits referred to above shall not in any way limit the liability of LICENSEE.

 

(c)
LICENSEE shall furnish UNIVERSITY with certificates of insurance showing compliance with all requirements. Such certificates shall:
(i) provide for thirty (30) days’ advance written notice to UNIVERSITY of any modification; (ii) indicate that UNIVERSITY
has been endorsed as an additionally insured party under the coverage referred to above; and (iii) include a provision that the
coverage shall be primary and shall not participate with nor shall be excess over any valid and collectable insurance or program
of self-insurance carried or maintained by UNIVERSITY.

 

(d)
UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which UNIVERSITY intends
to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims
under this Article. LICENSEE will not settle any claim against UNIVERSITY without UNIVERSITY’s written consent, where (a)
such settlement would include any admission of liability or wrongdoing on the part of UNIVERSITY or other indemnified party, (b)
such settlement would impose any restriction on UNIVERSITY/indemnified party’s conduct of any of its activities, or (c)
such settlement would not include an unconditional release of UNIVERSITY/indemnified party from all liability for claims that
are the subject matter of the settled claim.

 

ARTICLE
9. USE OF NAMES AND TRADEMARKS

 

9.1
Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name,
trade name, trademark, or other designation of UNIVERSITY by LICENSEE without prior written approval by UNIVERSITY (including
contraction, abbreviation or simulation of any of the foregoing).

 

9.2
LICENSEE hereby grants permission for UNIVERSITY (including UCSD) to include LICENSEE’s name and a link to LICENSEE’s
website in UNIVERSITY’s and UCSD’s annual reports and on UNIVERSITY’s (including UCSD’s) websites that
showcase innovation and commercialization stories.

 

    	-11-

    	 

    

 

ARTICLE
10. MISCELLANEOUS PROVISIONS

 

10.1
Correspondence. Any notice or payment required to be given to either party under this Agreement shall be deemed to have
been properly given and effective:

 

	 	(a)	on
    the date of delivery if delivered in person,
	 	 	 
	 	(b)	five
    (5) days after mailing if mailed by first-class or certified mail, postage paid, to the respective addresses given below,
    or to such other address as is designated by written notice given to the other party, or
	 	 	 
	 	(c)	upon
    confirmation by recognized national overnight courier, confirmed facsimile transmission, or confirmed electronic mail, to
    the following addresses or facsimile numbers of the parties.

 

	If
    sent to LICENSEE:
	 	TearLab
    Corporation
	 	9980
    Huennekens St., Suite 100
	 	San
    Diego, CA 92121
	 	Attention:
    Michael Marquez, CFO
	 	Phone:
    (855) 832-7522 x1603
	 	e-mail:
    mmarquez@tearlab.com
	 	 
	If
    sent to UNIVERSITY by mail:
	 	University
    of California, San Diego
	 	Office
    of Innovation and Commercialization
	 	9500
    Gilman Drive, Mail Code 0910
	 	La
    Jolla, CA 92093-0910
	 	Attention:
    Director
	 	 
	If
    sent to UNIVERSITY by overnight delivery:
	 	University
    of California, San Diego
	 	Office
    of Innovation and Commercialization
	 	10300
    North Torrey Pines Road
	 	Torrey
    Pines Center North, Third Floor
	 	La
    Jolla, CA 92037
	 	Attention:
    Director

 

10.2
Secrecy.

 

(a)
“Confidential Information” shall mean information relating to the Invention and disclosed by UNIVERSITY to LICENSEE
during the term of this Agreement, which if disclosed in writing shall be marked “Confidential”, or if first disclosed
otherwise, shall within thirty (30) days of such disclosure be reduced to writing by UNIVERSITY and sent to LICENSEE.

 

(b)
LICENSEE shall:

 

(i)
use the Confidential Information for the sole purpose of performing under the terms of this Agreement;

 

(ii)
safeguard Confidential Information against disclosure to others with the same degree of care as it exercises with its own data
of a similar nature;

 

(iii)
not disclose Confidential Information to others (except to its employees, agents or consultants who are bound to LICENSEE by a
like obligation of confidentiality) without the express written permission of UNIVERSITY, except that LICENSEE shall not be prevented
from using or disclosing any of the Confidential Information that:

 

    	-12-

    	 

    

 

	 	(A)	LICENSEE
    can demonstrate by written records was previously known to it; 
	 	 	 
	 	(B)	is
    now, or becomes in the future, public knowledge other than through acts or omissions of LICENSEE; 
	 	 	 
	 	(C)	is
    lawfully obtained by LICENSEE from sources independent of UNIVERSITY; or
	 	 	 
	 	(D)	is
    required to be disclosed by law or a court of competent jurisdiction.

 

(c)
The secrecy obligations of LICENSEE with respect to Confidential Information shall continue for a period ending five (5) years
from the termination date of this Agreement.

 

(d)
Notwithstanding the foregoing, UNIVERSITY may disclose to the Inventors, senior administrators employed by UNIVERSITY, and individual
Regents the terms and conditions of this Agreement upon their request. If such disclosure is made, UNIVERSITY shall request the
individuals not disclose such terms and conditions to others. UNIVERSITY may acknowledge the existence of this Agreement and the
extent of the grant in Article 2 to third parties, but UNIVERSITY shall not disclose the negotiable financial terms of this Agreement
to third parties, except where UNIVERSITY is required by law to do so, such as under the California Public Records Act.

 

10.3
Assignability. This Agreement may be assigned by UNIVERSITY, but is personal to LICENSEE and assignable by LICENSEE only
with the written consent of UNIVERSITY. Notwithstanding anything to the contrary in the foregoing, the consent of University will
not be required if the assignment by LICENSEE is either to an Affiliate or in conjunction with the transfer of all or substantially
all of the business of LICENSEE to which this Agreement relates.

 

10.4
No Waiver. No waiver by either party of any breach or default of any agreement set forth in this Agreement shall be deemed
a waiver as to any subsequent and/or similar breach or default.

 

10.5
Failure to Perform. In the event of a failure of performance due under this Agreement and if it becomes necessary for either
party to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable
attorneys’ fees in addition to costs and necessary disbursements.

 

10.6
Governing Laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA,
but the scope and validity of any patent or patent application shall be governed by the applicable laws of the country of the
patent or patent application.

 

10.7
Force Majeure. A party to this Agreement may be excused from any performance required herein if such performance is rendered
impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation,
war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor
disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party’s
obligations herein shall resume.

 

10.8
Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to be
a part of or to affect the meaning or interpretation of this Agreement.

 

    	-13-

    	 

    

 

10.9
Entire Agreement. This Agreement, including Exhibits A and B, embodies the entire understanding of the parties and supersedes
all previous communications, representations or understandings, either oral or written, between the parties relating to the subject
matter hereof.

 

10.10
Amendments. No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing
and signed on behalf of each party.

 

10.11
Severability. In the event that any of the provisions contained in this Agreement is held to be invalid, illegal, or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this
Agreement shall be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it.

 

	TEARLAB
    CORPORATION:	 	THE
    REGENTS OF THE UNIVERSITY
    OF CALIFORNIA:
	 	 	 
	By:	/s/
    Seph Jensen 	 	By:	/s/
    Rubén D. Flores-Saaib
		(Signature)	 		(Signature)
	 	 	 	 	 
	Name:	Seph Jensen 	 	Rubén
    D. Flores-Saaib, Ph.D.
	 	 	 	 	 
	Title:	CEO	 	Director-Office
    of Innovation and Commercialization
	 	 	 	 	 
	Date:	5/1/18	 	Date:	04/26/2018

 

    	-14-

    	 

    

 

Exhibit
A – Patent Rights

 

	UCSD

        Docket
	 	Application
    Number	 	Patent
    Number	 	Filing
    Date	 	Country	 	Inventor	 	Title
	2002-180-
    1EP	 	03728299.3	 	 	 	03/25/2003	 	EPO	 	Benjamin
    Sullivan	 	Tear
    film osmometry
	2002-180
    - 1EP1	 	10184812.5	 	 	 	03/25/2003	 	EPO	 	Benjamin Sullivan	 	Tear
    film osmometry
	2002-180-3	 	10/400617	 	7017394	 	03/25/2003	 	United
    States	 	Benjamin
    Sullivan	 	Tear
    film osmometry
	2002-180-5	 	10/810780	 	7111502	 	03/25/2004	 	United
    States	 	Eric
    Donsky, Benjamin Sullivan	 	Systems
and methods for reducing the effect of corruptive signals during nanoliter osmometry

	2002-180-6	 	11/358986	 	7574902	 	02/21/2006	 	United
    States	 	Benjamin
    Sullivan	 	Tear
    film osmometry
	2002-
    180-9	 	12/435193	 	7987702	 	05/04/2009	 	United
    States	 	Benjamin
                                         Sullivan
	 	Tear
    film osmometry

 

    	-15-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]